Inhibrx Biosciences, Inc. INBX Operating Lease Liability Payments - 2025 (Lessee)

Operating Lease Liability Payments - 2025 (Lessee) at other companies

Nuvation BioNUVB

——

Replimune GroupREPL

——

ImmunityBio, Inc.IBRX

——

BridgeBio PharmaBBIO

——

Crinetics PharmaceuticalsCRNX

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

See full

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

See full

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

See full

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

See full

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

See full

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s operating lease liability payments - 2025 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s operating lease liability payments - 2025 (lessee)?: Inhibrx Biosciences, Inc. (INBX) reported operating lease liability payments - 2025 (lessee) of $1.49M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s operating lease liability payments - 2025 (lessee) changed year-over-year?: Inhibrx Biosciences, Inc.'s operating lease liability payments - 2025 (lessee) decreased by 49.3% year-over-year, from $2.94M to $1.49M.